Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Parathyroid Hormone Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The parathyroid hormone market size has seen rapid expansion in recent years. It is anticipated to increase from $2.51 billion in 2025 to $2.8 billion in 2026, maintaining a compound annual growth rate (CAGR) of 11.5%. Historically, this expansion has been influenced by factors such as the restricted access to recombinant parathyroid hormone, limited patient awareness of the disease, a reliance on conventional vitamin D therapy, the development of hospital and clinic infrastructure, and an increase in post-surgical parathyroid complications.
The parathyroid hormone market is anticipated to undergo substantial expansion in the coming years, with its size projected to reach $4.4 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. This projected increase is attributed to factors such as the development of advanced parathyroid hormone analogues, the rising adoption of personalized medicine approaches, the expansion of hospital and specialty clinics, the integration of digital patient monitoring tools, and increasing government and healthcare initiatives aimed at addressing hypocalcemia and hypoparathyroidism. Key trends expected in the forecast period include a growing incidence of hypocalcemia and hypoparathyroidism, an increasing utilization of recombinant parathyroid hormone therapies, the growth in parathyroid hormone analogues for personalized treatment, the expansion of hospital and clinic-based parathyroid care programs, and a greater focus on post-surgical management and vitamin D supplementation.
Get A Free Sample Report With In-Depth Market Insights:
Parathyroid Hormone Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The parathyroid hormone market is anticipated to expand due to the rising number of older adults. This demographic, generally defined as individuals 65 years and above, often faces age-associated health issues necessitating specific care and assistance. Factors contributing to this demographic change include longer life expectancies, advancements in healthcare, and reduced birth rates, leading to a larger segment of elderly people within the population. For older adults, parathyroid hormone plays a crucial role in managing calcium levels and bone metabolism, thereby aiding in the prevention of osteoporosis and fractures, conditions prevalent among this age group. As an illustration, in January 2024, data from the Population Reference Bureau, a US-based nonprofit organization, indicated that the American population aged 65 and above is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Concurrently, this group’s proportion of the total population is also foreseen to climb from 17% to 23% over the identical timeframe. Consequently, the expanding geriatric population is a key factor propelling the expansion of the parathyroid hormone market.
Parathyroid Hormone Market Segment Landscape: Which Areas Lead Development?
The parathyroid hormone market covered in this report is segmented –
1) By Disease Type: Hypocalcemia, Hypoparathyroidism
2) By Product Type: Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues
3) By End-User: Hospitals, Clinics, Other End-Users
Subsegments:
1) By Hypocalcemia: Pseudohypoparathyroidism, Vitamin D Deficiency
2) By Hypoparathyroidism: Post-Surgical Hypoparathyroidism, Idiopathic Hypoparathyroidism
Parathyroid Hormone Market Innovation Trends Shaping Future Development
Leading companies within the parathyroid hormone market are concentrating on creating biosimilar versions of parathyroid-derived medications, including prodrugs of parathyroid hormone (PTH), to improve available therapies. A prodrug of parathyroid hormone (PTH) functions as an inactive substance that converts into active parathyroid hormone once administered, providing extended release and consistent therapeutic effects for both calcium management and bone integrity. As an illustration, in August 2024, Ascendis Pharma A/S, a biopharmaceutical firm headquartered in Denmark, declared that the Food & Drug Administration (FDA) had given its approval to YORVIPATH (palopegteriparatide), marking it as the inaugural and sole therapy for adult hypoparathyroidism. This prodrug, taken once daily, guarantees ongoing exposure to PTH, proving advantageous for approximately 70,000 to 90,000 patients across the United States. Ascendis Pharma, responsible for its production, offers patient assistance via its ascendis signature access program (A.S.A.P.) program; however, individuals using it are required to routinely check their serum calcium levels to detect possible hypercalcemia or hypocalcemia.
Parathyroid Hormone Market Industry Leaders And Competitive Landscape
Major companies operating in the parathyroid hormone market are Pfizer Inc., Eli Lilly and Company, Radius Health Inc., Ascendis Pharma, Entera Bio Ltd., Extend Biosciences Inc., Gedeon Richter Plc., Abbott Laboratories, Amgen Inc., Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Bayer Healthcare, AstraZeneca PLC, Biocon, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, Jubilant Life Sciences, Lupin Limited, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Wockhardt, Cipla Limited
View The Full Parathyroid Hormone Market Report:
Parathyroid Hormone Market Regional Analysis And Top Geography
North America was the largest region in the parathyroid hormone market in 2025. The Middle East is expected to be the fastest-growing region in the global parathyroid hormone market share during the forecast period. The regions covered in the parathyroid hormone market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
